Fostamatinib for persistent/chronic adult immune thrombocytopenia

Emerging drugs for immune thrombocytopenia (ITP)

(2017) Abdulgabar Salama   EXPERT OPINION ON EMERGING DRUGS

Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)

(2017) Anne Zufferey et al.   Journal of Clinical Medicine

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

(2016) Ian W. Flinn et al.   EUROPEAN JOURNAL OF CANCER

Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis

(2016) Indraraj Umesh Doobaree et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials

(2016) Sumit Kunwar et al.   RHEUMATOLOGY INTERNATIONAL

Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study

(2015) Mette Nørgaard et al.   BRITISH JOURNAL OF HAEMATOLOGY

OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy

(2014) Peter C Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

Costimulation of Dectin-1 and DC-SIGN Triggers the Arachidonic Acid Cascade in Human Monocyte-Derived Dendritic Cells

(2014) I. Valera et al.   JOURNAL OF IMMUNOLOGY

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-  Antagonist

(2014) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial

(2014) George D. Kitas et al.   Journal of the American Society of Hypertension

The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4+ T cell-priming capacity of dendritic cells

(2014) Andrew M. Platt et al.   RHEUMATOLOGY

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

(2014) Michael E. Weinblatt et al.   Arthritis & Rheumatology

The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation

(2013) M Skinner et al.   BRITISH JOURNAL OF PHARMACOLOGY

Immune Thrombocytopenia

(2013) Gaurav Kistangari et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment

(2012) W. Ghanima et al.   BLOOD

Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies

(2012) Muhammad Baluom et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Immune Thrombocytopenia: Pathophysiologic and Clinical Update

(2012) Roberto Stasi   SEMINARS IN THROMBOSIS AND HEMOSTASIS

The Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib Attenuates Inflammation and Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice

(2011) Ingo Hilgendorf et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

(2011) C. Neunert et al.   BLOOD

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Increased Number of Tc17 and Correlation with Th17 Cells in Patients with Immune Thrombocytopenia

(2011) Yu Hu et al.   PLoS One

Piecing Together the Humoral and Cellular Mechanisms of Immune Thrombocytopenia

(2011) Lisa Toltl et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

(2010) M. Suljagic et al.   BLOOD

Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP)

(2010) Ameet Sarpatwari et al.   BRITISH JOURNAL OF HAEMATOLOGY

Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation

(2010) D. J. Sweeny et al.   DRUG METABOLISM AND DISPOSITION

Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

(2010) A. Sarpatwari et al.   HAEMATOLOGICA

Therapeutic Targeting of Syk in Autoimmune Diabetes

(2010) L. Colonna et al.   JOURNAL OF IMMUNOLOGY

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

(2010) Michael E. Weinblatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

International consensus report on the investigation and management of primary immune thrombocytopenia

(2009) D. Provan et al.   BLOOD

The ITP syndrome: pathogenic and clinical diversity

(2009) D. B. Cines et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production

(2009) Diane Nugent et al.   BRITISH JOURNAL OF HAEMATOLOGY

Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcεRI-activated RBL-2H3 basophilic cells

(2009) Michael P. Sanderson et al.   CELLULAR IMMUNOLOGY

Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura

(2009) J. Zhang et al.   HAEMATOLOGICA

Antiplatelet Antibodies in Chronic Immune Thrombocytopenia and Their Role in Platelet Destruction and Defective Platelet Production

(2009) Robert McMillan   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial

(2008) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

(2008) Frances Rena Bahjat et al.   ARTHRITIS AND RHEUMATISM

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk

(2008) A. Podolanczuk et al.   BLOOD

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target

(2008) R. M. Young et al.   BLOOD

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

(2008) F. Rodeghiero et al.   BLOOD

Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey

(2008) Claire F. Snyder et al.   CURRENT MEDICAL RESEARCH AND OPINION

Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura

(2007) Robert McMillan et al.   AMERICAN JOURNAL OF HEMATOLOGY